Compare Tripadvisor Inc Common Stock (TRIP) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tripadvisor Inc Common Stock vs Zimmer Biomet Holdings Inc — how do they compare? Tripadvisor Inc Common Stock trades at $8.68 (market cap $1.01B), while Zimmer Biomet Holdings Inc trades at $89.07 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 16.8× Tripadvisor Inc Common Stock's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Tripadvisor Inc Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tripadvisor Inc Common Stock for 57 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| TRIP | ZBH | |
|---|---|---|
Market Cap | $1.01B | $16.95B |
Volume | 3,004,748 | 2,505,240 |
Sector | Consumer Cyclical | Health |
52-Week High | $16.72 | $103.98 |
52-Week Low | $8.04 | $79.58 |
Typical Hold Time | 57 Days | 89 Days |
Enterprise Value | $1.06B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TripAdvisor (TRIP) trades at $8.63, down 42% over the past year and near its 52-week low of $8.27. The stock shows bearish technical signals with recent earnings misses and declining revenue projections for 2026. Despite a low P/S ratio of 0.57, the company faces challenges from AI-driven competition eroding its core travel platform relevance.
The investment outlook remains cautious with analysts divided (21% Buy, 63% Hold) and a $13.58 price target suggesting 57% upside. Key risks include persistent search pressure, TheFork subsidiary sale execution, and competitive threats from AI travel tools. Positive cash flow from operations provides some stability amid the challenging transition.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
